Finch Therapeutics Group, Inc. (FNCH)
| Previous close | 1.9500 |
| Open | 1.9400 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.9216 - 2.0427 |
| 52-week range | 1.8600 - 16.7400 |
| Volume | |
| Avg. volume | 52,215 |
| Market cap | 3.115M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -9.8100 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Insider MonkeyBillionaire Seth Klarman’s Biotech Stock Picks
In this article, we discuss billionaire Seth Klarman’s biotech stock picks. To skip the detailed analysis of the biotech industry, Seth Klarman’s investment philosophy, and Baupost Group’s performance and Q3 bets, go directly to Billionaire Seth Klarman’s Top 4 Biotech Stock Picks. Biotechnology is the technology segment that utilizes cellular and biomolecular processes for the […]
GlobeNewswireFinch Announces Reverse Stock Split of Common Stock
BOSTON, June 09, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today announced it will effect a one-for-30 reverse stock split of its issued and outstanding common stock. Finch stockholders approved an amendment to its Amended and Restated Certificate of Incorporation to effect the reverse stock split at Finch’s Annual Meeting
